Hazem El-Osta
Overview
Explore the profile of Hazem El-Osta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2024 Aug;
19(11):1578-1579.
PMID: 39186030
No abstract available.
2.
Piccirillo M, Chu Q, Bradbury P, Tu W, Coschi C, Grosso F, et al.
J Thorac Oncol
. 2023 Feb;
18(6):813-819.
PMID: 36841541
Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro)...
3.
Velcheti V, Hu X, Li Y, El-Osta H, Pietanza M, Burke T
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205788
Our aim was to evaluate real-world time on treatment (rwToT), overall and by mutation status, with first-line pembrolizumab monotherapy for advanced non-small cell lung cancer (NSCLC) in real-world oncology practice...
4.
Jafri S, Ali F, Mollaeian A, Mojiz Hasan S, Hussain R, Akkanti B, et al.
Clin Med Insights Oncol
. 2019 May;
13:1179554919835798.
PMID: 31068757
Background: Lung cancer is the leading cause of cancer-related mortality and is strongly linked with smoking. We sought to determine whether major stressful life events (e.g. divorce) are also a...
5.
El-Osta H, Jafri S
Immunotherapy
. 2019 Feb;
11(3):189-199.
PMID: 30730276
Aim: In this meta-analysis, we evaluated several predictors of benefit to single-agent immune checkpoint inhibitors (ICIs) in metastatic non-small-cell lung cancer (NSCLC). Patients & Methods: Using the random-effect model, we...
6.
Circu M, Cardelli J, Barr M, OByrne K, Mills G, El-Osta H
PLoS One
. 2018 May;
13(5):e0197016.
PMID: 29718985
[This corrects the article DOI: 10.1371/journal.pone.0184922.].
7.
El-Osta H, Jani P, Mansour A, Rascoe P, Jafri S
Ann Am Thorac Soc
. 2018 Apr;
15(7):864-874.
PMID: 29684288
Rationale: An accurate assessment of the mediastinal lymph node status is essential in the staging and treatment planning of potentially resectable non-small-cell lung cancer. Objectives: We performed this meta-analysis to...
8.
Circu M, Cardelli J, Barr M, OByrne K, Mills G, El-Osta H
PLoS One
. 2017 Sep;
12(9):e0184922.
PMID: 28945807
Lung cancer is the leading cause of cancer-related deaths. Most patients develop resistance to platinum within several months of treatment. We investigated whether triggering lysosomal membrane permeabilization (LMP) or suppressing...
9.
Su J, Veillon D, Shackelford R, Cotelingam J, El-Osta H, Mills G, et al.
J La State Med Soc
. 2017 Jun;
169(3):68-70.
PMID: 28644154
Acute myeloid leukemia (AML) developing in patients with chronic lymphocytic leukemia (CLL) is very uncommon and usually associated with prior treatment. Acute promyelocytic leukemia (APL) accounts for a very small...
10.
Peddi P, Ajit N, Burton G, El-Osta H
BMJ Case Rep
. 2016 Dec;
2016.
PMID: 28011886
Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14.6 months by maximal safe resection with radiation and temozolamide. In the...